Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeutics, Inc. - Common Stock
(NQ:
ALDX
)
1.590
+0.070 (+4.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aldeyra Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
December 13, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
December 01, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
November 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder
↗
October 06, 2022
Via
Benzinga
Recap: Aldeyra Therapeutics Q2 Earnings
↗
August 05, 2022
Aldeyra Therapeutics (NASDAQ:ALDX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
November 03, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
October 26, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
↗
July 12, 2022
Via
Benzinga
Why Aldeyra Therapeutics' Shares Are Soaring Today?
↗
June 08, 2022
Via
Benzinga
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 06, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
October 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
↗
September 14, 2022
Via
Benzinga
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
September 14, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
September 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
↗
August 08, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
↗
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
August 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For August 5, 2022
↗
August 05, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million.
Via
Benzinga
Earnings Outlook For Aldeyra Therapeutics
↗
August 04, 2022
Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Aldeyra...
Via
Benzinga
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
July 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 12, 2022
Via
Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
↗
July 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
↗
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
July 12, 2022
Via
Benzinga
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
July 12, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
July 11, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 09, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
June 08, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
June 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
